Previous Close | 3.7200 |
Open | 3.7200 |
Bid | 1.7000 |
Ask | 5.4000 |
Strike | 5.00 |
Expire Date | 2024-07-19 |
Day's Range | 3.7200 - 3.7200 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.